Business Context and Reporting Period
Apyx Medical Corporation (APYX) filed a Form 8-K on March 10, 2026, to report its results of operations for the fourth quarter and full year ended December 31, 2025. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the earnings press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document serves solely as a notification that the results have been issued.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. It explicitly states that the information is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings press release dated March 10, 2026) for actual financial figures.
- Verify the specific revenue and net income figures for Q4 and full-year 2025 in the attached press release.
- Check for any forward-looking statements or guidance updates in the referenced press release.
- Confirm the company's cash position and debt levels as reported in the full earnings release.